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Translational research organizations (TROs) face specific challenges to secure resilience
and longevity. This perspective article provides the rationale for six hands-on
recommendations for the management of legitimacy building in TROs.
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INTRODUCTION: TRANSLATIONAL RESEARCH ORGANIZATIONS
IN NEED FOR LEGITIMACY
Translational medicine, defined as the innovation process of transferring the results of basic
research into clinical application, “covers a broad range of scientific, regulatory and clinical
disciplines” (1). Thus, the success of a translational process in medicine depends on a close
integration of stakeholders from industries, clinics, and academia as well as the involvement of
the relevant legal bodies and normative authorities (2–4). According to Polese and Capunzo’s
(5) system theory approach, successful translational medicine is characterized by the fact that
numerous actors from both the private and the public sectors benefit from the outcome of
joint activities within the same system. Such a system is sustainable only under the condition
that intrasystemic relationships lead to results that benefit the actors and therefore allow future
resources to be easily transferred to the system.
In line with these findings, both politics and science promote the organizational form of
public–private partnership (PPP) for the advancement of translational medicine. Whereas, private
organizations aim to implement their strategies effectively and efficiently, public organizationsmust
also do justice to the democratic principles of popular control and participation. One key challenge
is therefore how a translational research organization (TRO), organized as a PPP and thereby a
hybrid in terms of the dichotomy of economic principles and democracy, may gain legitimacy.
In fact, legitimacy is the property that is most important to the sustainable success of a hybrid
organization (6). Legitimacy does not exist per se. An organization is legitimate only if it enjoys
trust as a precondition for the creation of stable relationships among its stakeholders and target
population. In the following, we present the Swiss Institute for Translational and Entrepreneurial
Medicine (sitem-insel) in Bern, Switzerland, as an empirical case of a TRO (7), before we derive
eight types of legitimacy from the literature and apply them to the illustrative case to formulate six
hands-on recommendations for TRO practitioners.
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THE SITEM-INSEL CASE
The sitem-insel, located in the Swiss capital, Bern, qualifies
as an exemplary PPP: Representatives from private industries
and public universities and clinics have in 2014 joined forces
to establish the sitem-insel as a non-profit limited company
under private law. As part of the same system, these actors
expect the sitem-insel to contribute to the growth of the
medtech and biotech industries and to thereby generate jobs
as well as new products and services in favor of patients. In
view of these benefits, shareholders from both the public and
the private sectors hold shares worth approximately CHF 12
Mio, while the Swiss Confederation and the canton (state)
of Bern subsidized sitem-insel between 2017 and 2020 with
approximately CHF 25 Mio each.
With the aim to promote translational medicine, a new
building has recently been constructed on the campus of the Bern
University Hospital called “Inselspital”—hence the name sitem-
insel. The building provides state-of-the-art research laboratory
infrastructure on a surface of ∼20,000 m2 to foster cooperation
between partners from the healthcare industry and research
groups from hospital clinics and university institutes. They
cover various fields including neurology, radiology, anatomy,
dental medicine, microbiology, endocrinology, biotherapeutics,
and a clinical trials unit. While the sitem-insel is responsible
for funding the core and shell of the building, the platforms
are funded by renters from the private industry and public
organizations. The sitem-insel thereby aims to allow its
partners to capitalize on economies of scale and to reduce
their translational projects’ overall cycle time when bringing
innovation to the patient by immersion in the clinical and
academic environment.
As a condition for its sustainability, the sitem-insel needs
political, financial, and substantive support of its public and
private stakeholders. This presupposes sitem-insel’s need for
legitimacy. In the following, we present several types of
legitimacy and illustrate how sitem-insel as a prototypical case
of a TRO can make use of them.
TYPES OF ORGANIZATIONAL LEGITIMACY
According to Suchman (8), legitimacy is “a generalized
perception or assumption, that the actions of an entity are
desirable, proper, or appropriate within some socially constructed
system of norms, beliefs, and definitions.” Distinguishing the
three categories of pragmatic, moral, and cognitive legitimacy,
one can discern eight mutually overlapping and reinforcing
legitimacy types.
Pragmatic Legitimacy
The basis of pragmatic legitimacy is the self-interest that an
organization’s instrumental value promises to satisfy. Specific
policies, services, and goods have an instrumental value that
organizations may trade with their audiences. This is what
Suchman calls exchange legitimacy. At a higher level, Suchman
(8) speaks of influence legitimacy when the organization is
perceived to respond to the larger interest.
Moral Legitimacy
Moral legitimacy is based on normative evaluation, resting
on the congruence between collectively held norms
and an organization’s achievements. First, consequential
legitimacy regards an organization’s achievements in terms of
“consequential effectiveness” (8). Second, procedural legitimacy
stems from an organization’s practices perceived to be sound
and professional. Third, structural legitimacy asks whether an
organization promises to be the “right organization for the
job.” Finally, an organization’s personal legitimacy stems from
the charisma, credibility, and appeal of its leaders as “moral
entrepreneurs” (8).
Cognitive Legitimacy
Cognitive legitimacy denotes whether an organization’s role
in the environment finds acceptance. When its environment
deems an organization’s goals desirable, Suchman speaks of
comprehensibility legitimacy. An organization may also just be
“taken for granted” (8). Such taken-for-granted legitimacy does
not depend on evaluation. It therefore is the most powerful form
of legitimacy. However, at the same time, it also is extremely rare.
HOW TO GET THERE: LEGITIMACY
BUILDING FOR THE TRO
Our framework offers different strategies for legitimacy building
in TROs that we illustrate with the sitem-insel case as a
prototypical case.
How to Build Pragmatic Legitimacy
The TRO should secure long-term, process-oriented stakeholder
involvement to build exchange legitimacy and influence
legitimacy. As PPPs are accountable to both market demands and
state institutions, they assemble stakeholders with heterogeneous
interests. This diversity may lead stakeholders to seek the lowest
common denominator, which may differ from the intentions
of individual stakeholders. Managers of TROs should therefore
flexibly cooperate with stakeholders and acknowledge their
different ambitions. The sitem-insel must know its clients,
constituencies, and members to protect their interests. It
should include relevant actors, such as political incumbents and
administrative officeholders, private industry representatives,
experts, and members of the civil society in decision-making
processes and implementation. Exchange platforms can support
its diverse stakeholders in the deliberation of strategic objectives.
This inclusion is an investment into the implementation of these
objectives as it leads to reliable expectations and establishes
binding rules for the interaction among actors.
As sitem-insel aims to establish an innovation hub for
translational medicine in the long run, priority must be assigned
to the inclusion of powerful stakeholders. First, the support of the
relevant legal bodies and normative authorities must be ensured.
The sitem-insel apparently has this support, which materialized
in subsidies of approximately CHF 50 Mio. The second priority
of stakeholder inclusion lies with stakeholders as investors,
before, third, less decisive players should have the opportunity
to participate as well. This process may be oriented toward
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conformism, i.e., the aim of following “dictates of preexisting
audiences within the organization’s current environment” (8).
Accordingly, the involvement of the Inselspital’s head of clinics
as the main shareholder was an important basic decision for the
sustainable development of the sitem-insel, quite simply because
the clinical physicians are important drivers of translation
in medicine. In addition, the sitem-insel may concentrate on
cooperation with Bern-based partners such as local companies
and institutes of the university, before extending the network to
national and international levels.
How to Build Moral Legitimacy
Consequential legitimacy has to do with the TRO’s instrumental
performance. Pozen and Kline (9) suggest several measurable
aims TRO’s must achieve to perform in compliance with
their audience’s expectations. These aims include funding and
commercial investment, size and quality of the organization’s
staff, talent turnover, number and importance of new
collaborations, the volume of pipeline (i.e., new projects)
and its progress, the number of patents and publications, and
the knowledge transfer of innovation. Accordingly, the sitem-
insel’s key performance indicators measure not only output
performance but also the organization’s impact.
Personal legitimacy refers to the support for an organization’s
leaders because of their credibility and appeal. In this context, the
sitem-insel needs staff at the strategic level, from both the public
and the private sectors, who assume the role of legitimization
promoters. For instance, it makes sense to involve the head of
clinics, directors of university institutes, and senior executives
from the local industry in the board of directors and advisory
bodies. Due to their high hierarchical rank and reputation, they
can justify innovation processes, acquire the necessary resources,
and overcome the resiliency of change. There are not many
institutes of translational medicine in Switzerland. Consequently,
sitem-insel’s management board should additionally rely on
international experience in promoting translational medicine.
Procedural legitimacy stems from sound administrative
practices and professional routines. Accordingly, the sitem-
insel must not only incorporate substantive medical knowhow.
Including financial and entrepreneurial expertise is equally
important. In fact, sound financial programs as well as
unambiguous reporting and controlling processes are often
lacking within entrepreneurial public programs, even though
they are crucial for the performance of TROs (10). In this
context, for instance, it may be reasonable for the sitem-insel to
outsource audit and assurance, tax and legal, or financial advisory
to professional service firms.
Structural legitimacy has to do with the support of
organizational capacity. Most importantly, silo building must
be avoided. It therefore makes sense for the sitem-insel to
adopt a “flat and flexible structure wherein different departments
are interconnected” (11). Accordingly, a matrix organization
may serve as the appropriate knowledge-creating organizational
structure. Because innovation benefits from the inclusion of
stakeholders as they “realize better, more innovative solutions
by harnessing each other’s knowledge and expertise” (12), open
innovation platforms may be added to the TRO’s portfolio. In
general, the sitem-insel may perform mimetic isomorphism or,
in other words, imitate processes and structures of successful
TRO’s to promote translational and entrepreneurial medicine.
For instance, given the Inselspital’s powerful brand name in
Switzerland’s medical landscape, it was important to incorporate
the term “insel” into sitem-insel’s brand name. The physical
proximity of sitem-insel’s new building to the university hospital
is a major asset beyond branding, as the Inselspital campus
comprises all relevant tertiary medical disciplines.
How to Build Cognitive Legitimacy
Comprehensibility legitimacy refers to the support a TRO
enjoys thanks to its compliance with the cognitive scripts
and belief systems of its audience. As hybrid organizations,
TROs need to respond to various normative reference
systems such the state, society, and the market. All
discussed strategies add to gaining comprehensibility
TABLE 1 | Six recommendations for the management of legitimacy building in
TROs.
Legitimacy
category
Legitimacy type Explanation Recommendation
Pragmatic Influence and
exchange
Support for an
organization in
anticipation of its
responsiveness to
its audience’s
interest
1) Secure long-term,
process-oriented
stakeholder
involvement
Moral Consequential Support for an
organization
because of the
level of reward of
its policies
2) Serve instrumental
demands by
performance
reputation strategy
Personal Support for an
organization’s
leaders because of
their credibility and
appeal
3) Involve top staff at
the control level and
secure management
turnover
Procedural Support for an
organization’s
sound
administrative
practices and
professional
routines
4) Secure expertise in
financial
management and
business
administration
Structural Support for
capacity of
organizational
structure: Does
the organization
promise to work in
favor of the public?
5) Secure flat and
flexible organizational
structures
Cognitive Comprehensibility Support for an
organization’s
compliance with
cognitive scripts,
belief systems,
and perceived
reality
6) Imitate successful
hybrid organizations
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legitimacy. Finally, taken-for-granted legitimacy goes beyond
managerial control. It is a function of all other forms
of legitimacy.
CONCLUSION
TROs organized as PPPs are considered by stakeholders
of both the public and the private sectors as part of
a long-term solution to issues affecting society and the
economy at large. As TROs cannot rest upon a single reference
system like the market or the state alone, organizational
legitimacy is a precondition for their sustainable success.
However, legitimacy must be built. The presented strategies
provide practical guidance to do so. Our recommendations,
summarized in Table 1, may help TROs to fulfill their
vital role for the industry, academic medicine, and
health policy.
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